Endocarditis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 30: Line 30:
*Dose: 30 mg/kg I.V. daily in divided doses q. 12 hour for 4 weeks.
*Dose: 30 mg/kg I.V. daily in divided doses q. 12 hour for 4 weeks.


==Relatively Penicillin-Resistant Streptococci==
===Relatively Penicillin-Resistant Streptococci===
===If MIC 0.2–0.5 µg/ml===
If MIC 0.2–0.5 µg/ml:
====[[Penicillin]] G + [[gentamicin]]====
====[[Penicillin]] G + [[gentamicin]]====
*'''Dose''': [[Penicillin]] G, 20–30 million units I.V. daily in divided doses q. 4 hour for 4 weeks; [[gentamicin]], 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr for 2 wk (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).
*Dose: [[Penicillin]] G, 20–30 million units I.V. daily in divided doses q. 4 hour for 4 weeks; [[gentamicin]], 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr for 2 wk (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).


===If MIC > 0.5 µg/ml===
If MIC > 0.5 µg/ml:
====[[Penicillin]] G + [[gentamicin]]====
====[[Penicillin]] G + [[gentamicin]]====
*'''Dose''' is [[penicillin]] G, 20–30 million units I.V. daily in divided doses q. 4 hour for 4 week; [[gentamicin]], 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 4 week (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).
*Dose is [[penicillin]] G, 20–30 million units I.V. daily in divided doses q. 4 hour for 4 week; [[gentamicin]], 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 4 week (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).
====[[Vancomycin]]====
====[[Vancomycin]]====
*Regimen for patients with history of [[penicillin]] [[hypersensitivity]].
*Regimen for patients with history of [[penicillin]] [[hypersensitivity]].
*'''Dose''': 30 mg/kg I.V. daily in divided doses q. 12 hour for 4 weeks.
*Dose: 30 mg/kg I.V. daily in divided doses q. 12 hour for 4 weeks.


==Enterococci==
==Enterococci==

Revision as of 15:14, 17 December 2012

Endocarditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Infective Endocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

Diagnosis and Follow-up

Medical Therapy

Intervention

Case Studies

Case #1

Endocarditis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endocarditis medical therapy

CDC onEndocarditis medical therapy

Endocarditis medical therapy in the news

Blogs on Endocarditis medical therapy

to Hospitals Treating Endocarditis medical therapy

Risk calculators and risk factors for Endocarditis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Blood cultures should be drawn prior to instituting antibiotics to identify the etiologic agent and to determine its antimicrobial susceptibility. Older antibiotics such as penicillin G, ampicillin, nafcillin, cefazolin, gentamycin, ceftriaxone, rifampin and vancomycin are the mainstays of therapy.

Timing of Initiation of Antibiotics

Antibiotic therapy for subacute or indolent disease can be delayed until results of blood cultures are known; in fulminant infection or valvular dysfunction requiring urgent surgical intervention, begin empirical antibiotic therapy promptly after blood cultures have been obtained.

Duration of Antibiotic Therapy

The duration for native valve endocarditis is often 4 weeks. For prosthetic valve endocarditis (including the presence of a valve ring), treatment should be continued for 6 to 8 weeks. For each infective agent, the preferred antimicrobial agent, dose, and duration is listed below.

Treatment Based Upon Infectious Agent[1]

Penicillin-Susceptible Strep Viridans and Other Nonenterococcal Streptococci

Penicillin G

  • If Minimum inhibitory concentration [MIC] <0.2 µg/ml.
  • Dose: 12–18 million units I.V. daily in divided doses q. 4 hour for 4 weeks.

Penicillin G + gentamicin

  • Dose: Penicillin G, 12–18 million units I.V. daily in divided doses q. 4 hour for 4 weeks plus gentamicin, 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 2 weeks (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).

Ceftriaxone

  • Dose: 2 g I.V. daily as a single dose for 2 weeks.

Vancomycin

Relatively Penicillin-Resistant Streptococci

If MIC 0.2–0.5 µg/ml:

Penicillin G + gentamicin

  • Dose: Penicillin G, 20–30 million units I.V. daily in divided doses q. 4 hour for 4 weeks; gentamicin, 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr for 2 wk (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).

If MIC > 0.5 µg/ml:

Penicillin G + gentamicin

  • Dose is penicillin G, 20–30 million units I.V. daily in divided doses q. 4 hour for 4 week; gentamicin, 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 4 week (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).

Vancomycin

  • Regimen for patients with history of penicillin hypersensitivity.
  • Dose: 30 mg/kg I.V. daily in divided doses q. 12 hour for 4 weeks.

Enterococci

In general, treatment of enterococcal endocarditis requires combination therapy with two antibiotics:

Penicillin G + gentamicin

  • Dose is penicillin G, 20–30 million units I.V. daily in divided doses q. 4 hr for 4–6 weeks; gentamicin, 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 4–6 weeks (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).

Ampicillin + gentamicin

  • Dose is ampicillin, 12 g I.V. daily in divided doses q. 4 hour for 4–6 weeks; gentamicin, dose as above.

Vancomycin + gentamicin

Staphylococci (Methicillin Susceptible) in the Absence of Prosthetic Material

Nafcillin or oxacillin + gentamicin (optional)

  • Dose: Nafcillin or oxacillin, 12 g I.V. daily in divided doses q. 4 hour for 4–6 weeks; gentamicin, 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr for 3–5 days (peak serum concentration should be ~ 3 µg/ml and trough concentrations <1 µg/ml).

Cefazolin + gentamicin (optional)

Vancomycin

  • Alternative regimen for patients with history of penicillin hypersensitivity.
  • Dose: 30 mg/kg I.V. daily in divided doses q. 12 hr for 4–6 weeks.

Staphylococci (Methicillin Resistant) in the Absence of Prosthetic Material

Vancomycin

  • Dose: 30 mg/kg I.V. daily in divided doses q. 12 hour for 4–6 weeks.

Staphylococci (Methicillin Susceptible) in the Presence of Prosthetic Material

Nafcillin or oxacillin + rifampin + gentamicin

  • Dose: Nafcillin or oxacillin, 12 g I.V. daily in divided doses q. 4 hour for 6–8 weeks plus rifampin, 300 mg p.o., q. 8 hour for 6–8 weeks plus gentamicin (administer during the initial 2 weeks), 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 2 weeks.

Staphylococci (Methicillin Resistant) in the Presence of Prosthetic Material

Vancomycin + rifampin + gentamicin

  • Dose: Vancomycin, 30 mg/kg I.V. daily in divided doses q. 12 hour for 6–8 weeks plusrifampin, 300 mg p.o., q. 8 hour for 6–8 weeks plus gentamicin (administer during the initial 2 weeks), 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 2 weeks.

HACEK Organisms

These agents are more indolent and the infection is less complicated.

Ceftriaxone or another third-generation cephalosporin

  • Dose: 2 g I.V. daily as a single dose for 4 weeks.

Ampicillin-Sulbactam

Ciprofloxacin

  • This is listed as an alternative, there is not a lot of data to support its regular use.

References

  1. Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.

Template:WH Template:WS